menu
    • menu
    [{"orgOrder":0,"company":"Ergomed","sponsor":"Gesynta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GS-248","moa":"||mPGES-1","graph1":"Immunology","graph2":"Phase II","graph3":"Ergomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ergomed \/ Ergomed","highestDevelopmentStatusID":"8","companyTruncated":"Ergomed \/ Ergomed"}]

    Find Clinical Drug Pipeline Developments & Deals by Ergomed

    Menu

    Ergomed

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ergomed

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Ergomed

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GS-248,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : Gesynta Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 08, 2021

                            Lead Product(s) : GS-248,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : Gesynta Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ergomed

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Ergomed

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopregnanolone,Inapplicable

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Recipient : Asarina Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 05, 2018

                            Lead Product(s) : Allopregnanolone,Inapplicable

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Recipient : Asarina Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ergomed

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Ergomed

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sevuparin,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Modus Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            August 05, 2015

                            Lead Product(s) : Sevuparin,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Modus Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ergomed

                            United Kingdom arrow
                            EPSC
                            Not Confirmed

                            Ergomed

                            United Kingdom arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Purethal Birch,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Recipient : Ergomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PURETHAL Birch RUSH Study

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 08, 2013

                            Lead Product(s) : Purethal Birch,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Recipient : Ergomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth